Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Aquestive Therapeutics, Inc.    AQST

AQUESTIVE THERAPEUTICS, INC.

(AQST)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/03/2019 12/04/2019 12/05/2019 12/06/2019 12/09/2019 Date
8.75(c) 8.78(c) 8.34(c) 8.01(c) 7.73(c) Last
1 021 970 940 464 687 635 637 464 531 050 Volume
+0.11% +0.34% -5.01% -3.96% -3.50% Change
More quotes
Financials (USD)
Sales 2019 46,4 M
EBIT 2019 -53,4 M
Net income 2019 -65,6 M
Debt 2019 41,8 M
Yield 2019 -
Sales 2020 56,9 M
EBIT 2020 -48,8 M
Net income 2020 -54,2 M
Debt 2020 109 M
Yield 2020 -
P/E ratio 2019 -2,95x
P/E ratio 2020 -3,66x
EV / Sales2019 5,07x
EV / Sales2020 5,33x
Capitalization 194 M
More Financials
Company
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a... 
Sector
Pharmaceuticals
Calendar
12/09 | 08:00amPresentation
More about the company
Surperformance© ratings of Aquestive Therapeutics, In
Trading Rating : Investor Rating :
More Ratings
Latest news on AQUESTIVE THERAPEUTICS, IN
06:05aAQUESTIVE THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial..
AQ
12/05AQUESTIVE THERAPEUTICS : to Host Investor and Analyst Libervant Buccal Film Upda..
AQ
12/04Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam)..
GL
12/03AQUESTIVE THERAPEUTICS : Completes Rolling Submission of New Drug Application to..
AQ
12/02AQUESTIVE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
12/02AQUESTIVE THERAPEUTICS : Completes Rolling Submission of New Drug Application (N..
AQ
11/27AQUESTIVE THERAPEUTICS : Announces Poster Presentations of Data on Libervant Buc..
AQ
11/26AQUESTIVE THERAPEUTICS : Announces Poster Presentations of Data on Libervant&tra..
AQ
11/26AQUESTIVE THERAPEUTICS : Receives FDA Approval for Exservan Oral Film
AQ
11/25AQUESTIVE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
11/25Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) O..
GL
11/13AQUESTIVE THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements an..
AQ
11/13Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development ..
GL
11/05AQUESTIVE THERAPEUTICS : 3Q Earnings Snapshot
AQ
11/05AQUESTIVE THERAPEUTICS : Management's Discussion and Analysis of Financial Condi..
AQ
More news
News in other languages on AQUESTIVE THERAPEUTICS, IN
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Sector news : Pharmaceuticals - NEC
07:02pBig Drugmakers Push Deeper Into Cancer Treatment -- 4th Update
DJ
06:31pELANCO ANIMAL HEALTH INCORPORATED : Gets Second Request From FTC on Bayer Deal
DJ
05:28pSanofi ends research in diabetes, narrows units to spur profit
RE
04:59pSANOFI : Maker of World's Biggest Insulin, to Exit Diabetes Research
DJ
04:55pSANOFI : Maker of World's Biggest Insulin, to Exit Diabetes Research
DJ
More sector news : Pharmaceuticals - NEC
Chart AQUESTIVE THERAPEUTICS, INC.
Duration : Period :
Aquestive Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AQUESTIVE THERAPEUTICS, IN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 18,83  $
Last Close Price 7,73  $
Spread / Highest target 379%
Spread / Average Target 144%
Spread / Lowest Target 16,4%
EPS Revisions
Managers
NameTitle
Keith J. Kendall President, Chief Executive Officer & Director
Santo J. Costa Chairman
Daniel Barber Chief Operating Officer & Senior Vice President
John T. Maxwell Chief Financial Officer & Senior Vice President
A. Mark Schobel Chief Technology & Innovation Officer
Sector and Competitors
1st jan.Capitalization (M$)
AQUESTIVE THERAPEUTICS, INC.22.70%201
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
MERCK AND COMPANY16.28%226 211
PFIZER-12.28%211 902
NOVARTIS22.87%208 547